Contribution of MRI in the Evaluation of Apparent Diffusion Coefficient and Prediction of Response to Neoadjuvant Chemotherapy in Breast Cancer
Not Applicable
Withdrawn
- Conditions
- Assess the Variation of Apparent Diffusion Coefficient
- Registration Number
- NCT01956513
- Lead Sponsor
- Centre Jean Perrin
- Brief Summary
The main objective of the study is to assess the sensitivity and the specificity of the variation of apparent diffusion coefficient for prediction, after a course of neoadjuvant chemotherapy or after modification of the treatment sequence, the pathological response at the end of chemotherapy
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- Female
- Target Recruitment
- Not specified
Inclusion Criteria
- Age> 18 years.
- Patient suffering from a breast tumor, regardless of the stage and size
- Patient requiring neoadjuvant chemotherapy
- Patient has the ability to undergo 18F-FDG-PET at baseline, at end of cycle 1 and at the end of neoadjuvant treatment before surgery
- Compulsory affiliation to a social security system.
- Obtaining informed consent in writing, signed and dated.
Exclusion Criteria
- Patient with cognitive or psychiatric disorders.
- Patient deprived of liberty by a court or administrative.
- Patient with signs against the achievement of MRI, mammography and ultrasound
- Patient metastatic
- Patient with prior chemotherapy, radiotherapy and hormone therapy for her breast cancer
- Pregnant women, current lactation
- Patient suffering from uncontrolled diabetes (> 11 mmol / L)
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Variation of apparent diffusion coefficient before / after a cycle of neoadjuvant chemotherapy or before / after modification of the treatment sequence and correlated with histologic response One year
- Secondary Outcome Measures
Name Time Method